|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.57 EUR | +1.24% |
|
+4.00% | +1.72% |
| Mar. 13 | Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment | MT |
| Feb. 19 | Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... |  |
Almirall, S.A. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was EUR 674.6 million compared to EUR 633.8 million a year ago. Revenue was EUR 676.5 million compared to EUR 648 million a year ago.
Net income was EUR 13.6 million compared to EUR 10.9 million a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.72% | 1.92B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
ALMIRALL, S.A. 
